Sangamo Therapeutics Welcomes Dr. Lisa Rojkjaer as its Chief Medical Officer

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) is pleased to announce the appointment of Lisa Rojkjaer, M.D., as the company’s new Chief Medical Officer. An esteemed leader in the field of genomic medicine, Dr. Rojkjaer will serve on the Executive Leadership team and report to Chief Development Officer Nathalie Dubois-Stringfellow.

She succeeds Bettina Cockroft, M.D., M.B.A, who has moved on to pursue other opportunities. We thank Dr. Cockroft for her invaluable contributions to the company.

Sangamo is delighted to welcome Dr. Rojkjaer to the team. With her expertise in clinical development, drug development, and regulatory affairs, she will be a key player in advancing Sangamo’s Fabry program towards a potential Phase 3 trial, making progress on the TX200 CAR-Treg program in Phase 1/2, and developing a pre-clinical pipeline of epigenetic regulation for the central nervous system.

With her guidance, Sangamo is striving to create targeted genomic medicines that can potentially provide relief to patients suffering from serious genetic diseases with limited or no treatment options.

Dr. Rojkjaer brings an impressive wealth of experience to her leadership positions, having over two decades of global and regional clinical development, regulatory, and medical affairs experience, as well as an international clinical practice background. Most recently, she served as Chief Medical Officer of Viracta Therapeutics, but she has also held several senior roles in biotech and pharmaceutical companies.

For example, she was the Global Clinical Program Head at Novartis Oncology, where she led the development and approval of Rydapt®. She has also been the Chief Medical Officer of Nordic Nanovector, Molecular Partners, and MorphoSys AG, as well as the Director of Clinical Development, Hematology in the US and Head, Global Medical Affairs, Biopharmaceuticals at Novo Nordisk.

Dr. Rojkjaer is a highly qualified specialist, having earned her Doctor of Medicine degree from the University of Toronto and completing her internal medicine and hematology fellowships there as well. She is an expert in her field, dedicated to providing the highest quality of medical care to her patients.

About Sangamo Therapeutics

Sangamo Therapeutics is revolutionizing the treatment of diseases for which there are either inadequate or no current treatment options. Through the use of their cutting-edge genomic medicine pipeline and proprietary zinc finger genome engineering technology, Sangamo is pioneering a new era of medicine that promises to bring relief to countless patients.

Leave a Comment